Area of research
Rheumatology · Pathology and Forensic Medicine
Research interest
Research interests include Spondyloarthritis Studies and Treatments, Rheumatoid Arthritis Research and Therapies, Spine and Intervertebral Disc Pathology, and Psoriasis: Treatment and Pathogenesis.
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Reporting Sacroiliac Joint Imaging Performed for Known or Suspected Axial Spondyloarthritis: Assessment of SpondyloArthritis International Society Recommendations
Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS)
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
ASAS consensus definition of early axial spondyloarthritis
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a <scp>Time‐Shifted</scp> Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: <scp>10‐Year</scp> Results From the German Spondyloarthritis Inception Cohort
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis
Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
Sensitivity and Specificity of Autoantibodies Against <scp>CD</scp>74 in Nonradiographic Axial Spondyloarthritis
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice
The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns
Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Autoantibodies against CD74 in spondyloarthritis